In Bangalore, India, Berry Global will construct a second manufacturing site as well as a global healthcare centre of excellence.

The new facility, which will be built near Berry’s existing Bangalore business, which started in 2009, will be utilised to expand R&D and scale up manufacturing in many major healthcare areas, including ophthalmology, nasal pumps, inhalation, and injectable administrations.

The Increased capacity would also improve supplies in India and South Asia, addressing some of the world’s fastest-growing healthcare markets.

Berry Global’s Chairman and CEO, Tom Salmon, stated, “Investing in our global healthcare business in Bangalore is a critical step in serving our pharmaceutical, over-the-counter, and medical device customers linked to predicted market needs. We learnt during the pandemic that strategically situated sites throughout the world provide efficient localised assistance for customers of any size, and we believe this investment will help the patient populations in India and South Asia.”

The new building will also feature a specialised R&D Center of Excellence, in addition to precision production equipment. Aside from ensuring that dosing and administering medicines is simple and comfortable for the user, another important design requirement will be to support customers’ sustainability aspirations, with the existing Bangalore facility already being ISCC Plus accredited. Aside from ensuring that dosing and administering medicines is simple and comfortable for the user, another important design requirement will be to support customers’ sustainability aspirations, with the existing Bangalore facility already being ISCC Plus accredited. According to the ISCC organisation, this allows Berry to sell ISCC certified packaging and plastic components that contribute to a circular economy approach based on advanced recycling and mass balance. The mass balance approach allows for tracking the amount and sustainability characteristics of circular and/or bio-based content in the value chain and attribution based on verifiable bookkeeping. 

The new facility’s construction is planned to start later this year, with the site being validated and ready for production by the summer of 2023.